beta

AERI

Aerie Pharmaceuticals Inc.

Aeri

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

11-06-2018 after market close 08-08-2018 after market close 05-08-2018 after market close 02-28-2018 after market close 11-08-2017 after market close 08-01-2017 after market close 05-02-2017 after market close
Actual EPS -1.73 -1.4 -1.05 -1.38 -0.89 -0.82 -0.76
Consensus EPS -1.33 -1.02 -1.11 -1.29 -0.84 -0.74
Estimated EPS -1.33 -1.02 -1.11 -1.29 -0.84 -0.74
Number of Estimates 3 4 4 4 1 2
EPS Surprise -$0.40 -$0.38 $0.06 -$0.09 $0.02 -$0.02

Stats

Summary

Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is engaged in the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.

Market Cap: 2.17 Billion

Primary Exchange: NASDAQ Global Market

Website: http://www.aeriepharma.com

Shares Outstanding: 38 Million

Float: 37.2 Million

Dividend: 0.0 (0.0%)

Beta: 0.0

Sector: Healthcare

Industry: Drug Manufacturers

Short Interest (Jan 12, 2018): 3.95 Million

Ethical Flags

Animal testing

Longest drawdown: 355 trading days

From: 2015-04-23 To: 2016-09-19

Lowest Point:

Updating My Aerie Pharmaceuticals Short

via: SeekingAlpha at 2018-11-26 21:04:53:000

In June of this year, I explained why I was short Aerie Pharmaceuticals ( AERI ), which at the time was trading around $70 per share, and in August, I compared my short of Radius Health ( RDUS ) to the situation developing at AERI. Indeed, given the lessons learned from my RDUS short, I de… read more...

Updating My Aerie Pharmaceuticals Short

via: SeekingAlpha at 2018-11-26 21:04:53:000

In June of this year, I explained why I was short Aerie Pharmaceuticals ( AERI ), which at the time was trading around $70 per share, and in August, I compared my short of Radius Health ( RDUS ) to the situation developing at AERI. Indeed, given the lessons learned from my RDUS short, I de… read more...

Updating My Aerie Pharmaceuticals Short

via: SeekingAlpha at 2018-11-26 21:04:53:000

In June of this year, I explained why I was short Aerie Pharmaceuticals ( AERI ), which at the time was trading around $70 per share, and in August, I compared my short of Radius Health ( RDUS ) to the situation developing at AERI. Indeed, given the lessons learned from my RDUS short, I de… read more...

Leerink sees 34% upside in Allergan in premarket analyst action

via: SeekingAlpha at 2018-11-13 08:20:25:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Market Perform rating at Leerink Partners. More news on: ACADIA Pharmaceuticals Inc., AC Immune SA, Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Leerink sees 34% upside in Allergan in premarket analyst action

via: SeekingAlpha at 2018-11-13 08:20:25:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Market Perform rating at Leerink Partners. More news on: ACADIA Pharmaceuticals Inc., AC Immune SA, Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Leerink sees 34% upside in Allergan in premarket analyst action

via: SeekingAlpha at 2018-11-13 08:20:25:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Market Perform rating at Leerink Partners. More news on: ACADIA Pharmaceuticals Inc., AC Immune SA, Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Aerie Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference

via: Business Wire at 2018-11-07 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that … read more...

Aerie Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference

via: Business Wire at 2018-11-07 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that … read more...

Aerie Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference

via: Business Wire at 2018-11-07 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that … read more...

Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-06 23:44:07:000

Aerie Pharmaceuticals Inc (AERI) Q3 2018 Earnings Conference Call November 6, 2018 5:00 PM ET Executives Rich Rubino Chief Financial Officer Vince Anido Chairman and Chief Executive Officer Tom Mitro President and Chief Operating Officer Analysts … read more...

Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-06 23:44:07:000

Aerie Pharmaceuticals Inc (AERI) Q3 2018 Earnings Conference Call November 6, 2018 5:00 PM ET Executives Rich Rubino Chief Financial Officer Vince Anido Chairman and Chief Executive Officer Tom Mitro President and Chief Operating Officer Analysts … read more...

Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-06 23:44:07:000

Aerie Pharmaceuticals Inc (AERI) Q3 2018 Earnings Conference Call November 6, 2018 5:00 PM ET Executives Rich Rubino Chief Financial Officer Vince Anido Chairman and Chief Executive Officer Tom Mitro President and Chief Operating Officer Analysts … read more...

Aerie Pharmaceuticals misses by $0.36, beats on revenue

via: SeekingAlpha at 2018-11-06 16:27:54:000

Aerie Pharmaceuticals (NASDAQ: AERI ): Q3 Non-GAAP EPS of -$1.73 misses by $0.36 ; GAAP EPS of -$1.96 misses by $0.31 . Revenue of $7.3M beats by $1.42M . Press Release More news on: Aerie Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, read more...

Aerie Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

via: Business Wire at 2018-11-06 16:01:00:000

Conference Call and Webcast Today, November 6 th , at 5:00 p.m. ET Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle … read more...

This May Be A Good Time To Pick Up Aerie Pharmaceuticals In 2018

via: SeekingAlpha at 2018-10-30 22:59:21:000

Headquartered in Irvine, California, Aerie Pharmaceuticals ( AERI ) is an ophthalmic pharmaceutical company. The company is mainly focused on developing and commercializing therapies targeting glaucoma, retinal diseases, and other eye diseases. Aerie Pharmaceuticals today stands at the cusp … read more...

This May Be A Good Time To Pick Up Aerie Pharmaceuticals In 2018

via: SeekingAlpha at 2018-10-30 22:59:21:000

Headquartered in Irvine, California, Aerie Pharmaceuticals ( AERI ) is an ophthalmic pharmaceutical company. The company is mainly focused on developing and commercializing therapies targeting glaucoma, retinal diseases, and other eye diseases. Aerie Pharmaceuticals today stands at the cusp … read more...

This May Be A Good Time To Pick Up Aerie Pharmaceuticals In 2018

via: SeekingAlpha at 2018-10-30 22:59:21:000

Headquartered in Irvine, California, Aerie Pharmaceuticals ( AERI ) is an ophthalmic pharmaceutical company. The company is mainly focused on developing and commercializing therapies targeting glaucoma, retinal diseases, and other eye diseases. Aerie Pharmaceuticals today stands at the cusp … read more...

Aerie Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018

via: Business Wire at 2018-10-30 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its third quarter 2018 financial results will be released after the market closes on Tuesday, November 6, 2018. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. … read more...

Aerie Pharmaceuticals Establishes GMP PRINT® Production Facility in an Expanded Global Headquarters

via: Business Wire at 2018-10-23 06:30:00:000

The Company now occupies more than 60,000 sq. ft. of laboratory and office space at the Durham, North Carolina, facility Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class thera… read more...

Aerie Pharmaceuticals Establishes GMP PRINT® Production Facility in an Expanded Global Headquarters

via: Business Wire at 2018-10-23 06:30:00:000

The Company now occupies more than 60,000 sq. ft. of laboratory and office space at the Durham, North Carolina, facility Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class thera… read more...

Aerie Pharmaceuticals Establishes GMP PRINT® Production Facility in an Expanded Global Headquarters

via: Business Wire at 2018-10-23 06:30:00:000

The Company now occupies more than 60,000 sq. ft. of laboratory and office space at the Durham, North Carolina, facility Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class thera… read more...

Aerie Pharmaceuticals' MAA accepted for review in Europe

via: SeekingAlpha at 2018-10-09 07:07:53:000

Aerie Pharmaceuticals (NASDAQ: AERI ) reports that the EMA has accepted for review the Marketing Authorisation Application (MAA) for Rhokiinsa(netarsudil ophthalmic solution) 0.02%. More news on: Aerie Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

Aerie Pharmaceuticals' MAA accepted for review in Europe

via: SeekingAlpha at 2018-10-09 07:07:53:000

Aerie Pharmaceuticals (NASDAQ: AERI ) reports that the EMA has accepted for review the Marketing Authorisation Application (MAA) for Rhokiinsa(netarsudil ophthalmic solution) 0.02%. More news on: Aerie Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

Aerie Pharmaceuticals' MAA accepted for review in Europe

via: SeekingAlpha at 2018-10-09 07:07:53:000

Aerie Pharmaceuticals (NASDAQ: AERI ) reports that the EMA has accepted for review the Marketing Authorisation Application (MAA) for Rhokiinsa(netarsudil ophthalmic solution) 0.02%. More news on: Aerie Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

Aerie Pharmaceuticals, Inc. Announces Drug Application for Regulatory Approval Accepted for Review in Europe

via: Business Wire at 2018-10-09 06:30:00:000

European Medicines Agency (EMA) will begin review of the Marketing Authorisation Application (MAA) for Rhokiinsa (netarsudil ophthalmic solution) 0.02%, currently marketed as Rhopressa in the United States Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic ph… read more...

Aerie Pharmaceuticals, Inc. Announces Drug Application for Regulatory Approval Accepted for Review in Europe

via: Business Wire at 2018-10-09 06:30:00:000

European Medicines Agency (EMA) will begin review of the Marketing Authorisation Application (MAA) for Rhokiinsa (netarsudil ophthalmic solution) 0.02%, currently marketed as Rhopressa in the United States Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic ph… read more...

Aerie Pharmaceuticals, Inc. Announces Drug Application for Regulatory Approval Accepted for Review in Europe

via: Business Wire at 2018-10-09 06:30:00:000

European Medicines Agency (EMA) will begin review of the Marketing Authorisation Application (MAA) for Rhokiinsa (netarsudil ophthalmic solution) 0.02%, currently marketed as Rhopressa in the United States Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic ph… read more...

Aerie Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

via: Business Wire at 2018-09-25 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that … read more...

Aerie Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

via: Business Wire at 2018-09-25 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that … read more...

Aerie Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

via: Business Wire at 2018-09-25 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that … read more...

Aerie Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

via: Business Wire at 2018-09-25 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that … read more...

Aerie Pharmaceuticals Announces Appointment of Damien Monaghan, Quality Director

via: Business Wire at 2018-09-24 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the a… read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-09-14 09:18:21:000

Noteworthy events during the week of September 16 - 22 for healthcare investors. More news on: Teva Pharmaceutical Industries Limited, Pieris Pharmaceuticals, Inc., Verona Pharma plc, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-09-14 09:18:21:000

Noteworthy events during the week of September 16 - 22 for healthcare investors. More news on: Teva Pharmaceutical Industries Limited, Pieris Pharmaceuticals, Inc., Verona Pharma plc, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-09-14 09:18:21:000

Noteworthy events during the week of September 16 - 22 for healthcare investors. More news on: Teva Pharmaceutical Industries Limited, Pieris Pharmaceuticals, Inc., Verona Pharma plc, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-09-14 09:18:21:000

Noteworthy events during the week of September 16 - 22 for healthcare investors. More news on: Teva Pharmaceutical Industries Limited, Pieris Pharmaceuticals, Inc., Verona Pharma plc, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-09-14 09:18:21:000

Noteworthy events during the week of September 16 - 22 for healthcare investors. More news on: Teva Pharmaceutical Industries Limited, Pieris Pharmaceuticals, Inc., Verona Pharma plc, Healthcare stocks news, , Read more … read more...

FDA OKs Sun Pharma's Xelpros for lowering IOP in glaucoma patients

via: SeekingAlpha at 2018-09-14 07:21:48:000

The FDA approves Sun Pharmaceuticals' ( OTCPK:SMPQY ) XELPROS (latanoprost ophthalmic emulsion) 0.005% for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. More news on: Sun Pharmaceuticals Industries Ltd. ADR, Aerie Pharmaceuticals, Inc… read more...

FDA OKs Sun Pharma's Xelpros for lowering IOP in glaucoma patients

via: SeekingAlpha at 2018-09-14 07:21:48:000

The FDA approves Sun Pharmaceuticals' ( OTCPK:SMPQY ) XELPROS (latanoprost ophthalmic emulsion) 0.005% for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. More news on: Sun Pharmaceuticals Industries Ltd. ADR, Aerie Pharmaceuticals, Inc… read more...

FDA OKs Sun Pharma's Xelpros for lowering IOP in glaucoma patients

via: SeekingAlpha at 2018-09-14 07:21:48:000

The FDA approves Sun Pharmaceuticals' ( OTCPK:SMPQY ) XELPROS (latanoprost ophthalmic emulsion) 0.005% for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. More news on: Sun Pharmaceuticals Industries Ltd. ADR, Aerie Pharmaceuticals, Inc… read more...

FDA OKs Sun Pharma's Xelpros for lowering IOP in glaucoma patients

via: SeekingAlpha at 2018-09-14 07:21:48:000

The FDA approves Sun Pharmaceuticals' ( OTCPK:SMPQY ) XELPROS (latanoprost ophthalmic emulsion) 0.005% for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. More news on: Sun Pharmaceuticals Industries Ltd. ADR, Aerie Pharmaceuticals, Inc… read more...

FDA OKs Sun Pharma's Xelpros for lowering IOP in glaucoma patients

via: SeekingAlpha at 2018-09-14 07:21:48:000

The FDA approves Sun Pharmaceuticals' ( OTCPK:SMPQY ) XELPROS (latanoprost ophthalmic emulsion) 0.005% for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. More news on: Sun Pharmaceuticals Industries Ltd. ADR, Aerie Pharmaceuticals, Inc… read more...

Aerie Pharmaceuticals to Present at Ophthalmology Futures Forums in Vienna, Austria

via: Business Wire at 2018-09-13 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that… read more...

Aerie Pharmaceuticals Appoints David W. Gryska to the Company's Board of Directors

via: Business Wire at 2018-09-12 16:01:00:000

Aerie Pharmaceuticals, Inc.(NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced&… read more...

Aerie Pharmaceuticals Announces Appointment of Robert Finan as Director of Finance

via: Business Wire at 2018-09-11 16:01:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the a… read more...

2 Approaches To BioPharma: Interview With TPT Collaborators Amit Ghate And Zach Hartman

via: SeekingAlpha at 2018-09-10 13:10:06:000

Thanks for joining us today! Welcome to Dr Zach Hartman and Amit Ghate , two well-known analysts on SeekingAlpha, and very luckily for us here at the Total Pharma Tracker , our two outstanding collaborators. Amit has a mostly short-focused style, and he dabbles in the biopharma sector … read more...

Aerie Pharmaceuticals Announces Appointment of Thomas A. Shepard as Vice President, Implant Manufacturing

via: Business Wire at 2018-09-10 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the a… read more...

Closing Out My Radius Health Short With Lessons Learned

via: SeekingAlpha at 2018-08-24 08:22:49:000

Ive recently closed out my Radius Health ( RDUS ) short position which I initiated in December of 2014 at a price of about $37. Though the trade was profitable (I closed out at around $20.50), it wasnt really successful. In this article Id like to dissect the trade, inc… read more...

Closing Out My Radius Health Short With Lessons Learned

via: SeekingAlpha at 2018-08-24 08:22:49:000

Ive recently closed out my Radius Health ( RDUS ) short position which I initiated in December of 2014 at a price of about $37. Though the trade was profitable (I closed out at around $20.50), it wasnt really successful. In this article Id like to dissect the trade, inc… read more...

Closing Out My Radius Health Short With Lessons Learned

via: SeekingAlpha at 2018-08-24 08:22:49:000

Ive recently closed out my Radius Health ( RDUS ) short position which I initiated in December of 2014 at a price of about $37. Though the trade was profitable (I closed out at around $20.50), it wasnt really successful. In this article Id like to dissect the trade, inc… read more...

Closing Out My Radius Health Short With Lessons Learned

via: SeekingAlpha at 2018-08-24 08:22:49:000

Ive recently closed out my Radius Health ( RDUS ) short position which I initiated in December of 2014 at a price of about $37. Though the trade was profitable (I closed out at around $20.50), it wasnt really successful. In this article Id like to dissect the trade, inc… read more...

Closing Out My Radius Health Short With Lessons Learned

via: SeekingAlpha at 2018-08-24 08:22:49:000

Ive recently closed out my Radius Health ( RDUS ) short position which I initiated in December of 2014 at a price of about $37. Though the trade was profitable (I closed out at around $20.50), it wasnt really successful. In this article Id like to dissect the trade, inc… read more...

Aerie Pharmaceuticals Announces Appointment of Jeffrey White, Ph.D. as Director, Toxicology and Pharmacokinetics

via: Business Wire at 2018-08-20 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the a… read more...

Aerie Pharmaceuticals Announces Appointment of Jeffrey White, Ph.D. as Director, Toxicology and Pharmacokinetics

via: Business Wire at 2018-08-20 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the a… read more...

Aerie Pharmaceuticals Announces Appointment of Jeffrey White, Ph.D. as Director, Toxicology and Pharmacokinetics

via: Business Wire at 2018-08-20 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the a… read more...

Your Daily Pharma Scoop: Catalyst Positive, JNJ Succeeds, Blue Chips Support Tilray

via: SeekingAlpha at 2018-08-18 20:56:33:000

Stocks in News: CBIO, JNJ Catalyst Bio's MarzAA continues to shows positive action in hemophilia study; shares up 4% premarket Discussion: Catalyst Biosciences ( CBIO ) presented updated preliminary at the Hemophilia Drug Development Summit in Boston from Phase 2/3 clinical trial asses… read more...

Study results confirm mechanism of action of Aerie's Rhopressa

via: SeekingAlpha at 2018-08-15 08:05:18:000

Results from a Phase 2 study confirmed that Aerie Pharmaceuticals' (NASDAQ: AERI ) Rhopressa (netarsudil ophthalmic solution) 0.02% lowered intraocular pressure in patients with open-angle glaucoma or ocular hypertension via its effects on trabecular meshwork outflow. Specifically, trea… read more...

Study results confirm mechanism of action of Aerie's Rhopressa

via: SeekingAlpha at 2018-08-15 08:05:18:000

Results from a Phase 2 study confirmed that Aerie Pharmaceuticals' (NASDAQ: AERI ) Rhopressa (netarsudil ophthalmic solution) 0.02% lowered intraocular pressure in patients with open-angle glaucoma or ocular hypertension via its effects on trabecular meshwork outflow. Specifically, trea… read more...

Study results confirm mechanism of action of Aerie's Rhopressa

via: SeekingAlpha at 2018-08-15 08:05:18:000

Results from a Phase 2 study confirmed that Aerie Pharmaceuticals' (NASDAQ: AERI ) Rhopressa (netarsudil ophthalmic solution) 0.02% lowered intraocular pressure in patients with open-angle glaucoma or ocular hypertension via its effects on trabecular meshwork outflow. Specifically, trea… read more...

Aerie Pharmaceuticals Reports Topline Result from Rhopressa® Mechanism of Action Study

via: Business Wire at 2018-08-15 06:30:00:000

Clinical confirmation of the effect of Rhopressa on trabecular meshwork outflow facility in patients with open-angle glaucoma or ocular hypertension Aerie Pharmaceuticals, Inc.(NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and com… read more...

Aerie Pharmaceuticals Reports Topline Result from Rhopressa® Mechanism of Action Study

via: Business Wire at 2018-08-15 06:30:00:000

Clinical confirmation of the effect of Rhopressa on trabecular meshwork outflow facility in patients with open-angle glaucoma or ocular hypertension Aerie Pharmaceuticals, Inc.(NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and com… read more...

Aerie Pharmaceuticals Reports Topline Result from Rhopressa® Mechanism of Action Study

via: Business Wire at 2018-08-15 06:30:00:000

Clinical confirmation of the effect of Rhopressa on trabecular meshwork outflow facility in patients with open-angle glaucoma or ocular hypertension Aerie Pharmaceuticals, Inc.(NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and com… read more...

Aerie Pharmaceuticals Inc (AERI) CEO Vince Anido on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-09 00:50:07:000

Aerie Pharmaceuticals Inc (AERI) Q2 2018 Earnings Conference Call August 8, 2018 17:00 ET Executives Rich Rubino - Chief Financial Officer Vince Anido - Chairman and Chief Executive Officer Tom Mitro - President and Chief Operating Officer John LaRocca - General Counsel Anal… read more...

Aerie Pharmaceuticals Inc (AERI) CEO Vince Anido on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-09 00:50:07:000

Aerie Pharmaceuticals Inc (AERI) Q2 2018 Earnings Conference Call August 8, 2018 17:00 ET Executives Rich Rubino - Chief Financial Officer Vince Anido - Chairman and Chief Executive Officer Tom Mitro - President and Chief Operating Officer John LaRocca - General Counsel Anal… read more...

Aerie Pharmaceuticals Inc (AERI) CEO Vince Anido on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-09 00:50:07:000

Aerie Pharmaceuticals Inc (AERI) Q2 2018 Earnings Conference Call August 8, 2018 17:00 ET Executives Rich Rubino - Chief Financial Officer Vince Anido - Chairman and Chief Executive Officer Tom Mitro - President and Chief Operating Officer John LaRocca - General Counsel Anal… read more...

Aerie Pharmaceuticals misses by $0.16, beats on revenue

via: SeekingAlpha at 2018-08-08 16:03:57:000

Aerie Pharmaceuticals (NASDAQ: AERI ): Q2 EPS of -$1.14 misses by $0.16 . More news on: Aerie Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Aerie Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

via: Business Wire at 2018-08-08 16:01:00:000

Conference Call and Webcast Today, August 8 th , at 5:00 p.m. ET Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle gl… read more...

Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference

via: Business Wire at 2018-08-02 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that … read more...

Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference

via: Business Wire at 2018-08-02 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that … read more...

Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference

via: Business Wire at 2018-08-02 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that … read more...

Aerie Pharma expands collaboration with DSM Medical, licenses polymer technology

via: SeekingAlpha at 2018-08-01 07:42:43:000

Citing encouraging preclinical results for small molecule AR-13503, Aerie Pharmaceuticals (NASDAQ: AERI ) expands its 2017 collaboration with DSM Biomedical, the developer of bioerodible polyesteramide polymer technology that supports potential six-month intravitreal dosing for patients wi… read more...

Aerie Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Wednesday, August 8, 2018

via: Business Wire at 2018-08-01 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its second quarter 2018 financial results will be released after the market closes on Wednesday, August 8, 2018. Following the release, the Company will host a live conference call and webcast at 5:00 p.m…. read more...

Aerie Pharmaceuticals, Inc. and DSM Biomedical, Inc. Expand Collaboration Agreement Focused on Novel Drug Delivery Technology in Ophthalmology

via: Business Wire at 2018-08-01 06:30:00:000

Promising Technology Platform to Potentially Deliver Therapies to Treat a Broad Spectrum of Ophthalmic Diseases Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for t… read more...

Aerie Pharmaceuticals announces debt conversion and new credit facility with Deerfield

via: SeekingAlpha at 2018-07-23 09:48:19:000

Aerie Pharmaceuticals ( AERI ) announces the conversion of $125M of senior secured convertible notes held by affiliates of Deerfield Management Company L.P. into 5.04M and 0.33M common shares, thereby increasing the number of outstanding shares to 45.21M . More news on: Aerie Pharmaceuti… read more...

Aerie Pharmaceuticals announces debt conversion and new credit facility with Deerfield

via: SeekingAlpha at 2018-07-23 09:48:19:000

Aerie Pharmaceuticals ( AERI ) announces the conversion of $125M of senior secured convertible notes held by affiliates of Deerfield Management Company L.P. into 5.04M and 0.33M common shares, thereby increasing the number of outstanding shares to 45.21M . More news on: Aerie Pharmaceuti… read more...

Aerie Pharmaceuticals announces debt conversion and new credit facility with Deerfield

via: SeekingAlpha at 2018-07-23 09:48:19:000

Aerie Pharmaceuticals ( AERI ) announces the conversion of $125M of senior secured convertible notes held by affiliates of Deerfield Management Company L.P. into 5.04M and 0.33M common shares, thereby increasing the number of outstanding shares to 45.21M . More news on: Aerie Pharmaceuti… read more...

Aerie Pharmaceuticals announces debt conversion and new credit facility with Deerfield

via: SeekingAlpha at 2018-07-23 09:48:19:000

Aerie Pharmaceuticals ( AERI ) announces the conversion of $125M of senior secured convertible notes held by affiliates of Deerfield Management Company L.P. into 5.04M and 0.33M common shares, thereby increasing the number of outstanding shares to 45.21M . More news on: Aerie Pharmaceuti… read more...

Aerie Pharmaceuticals Announces Deerfield's Conversion of Convertible Notes into Aerie Common Stock and Establishment of an Undrawn $100M Credit Facility with Deerfield

via: Business Wire at 2018-07-23 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that … read more...

Aerie Pharmaceuticals Announces Deerfield's Conversion of Convertible Notes into Aerie Common Stock and Establishment of an Undrawn $100M Credit Facility with Deerfield

via: Business Wire at 2018-07-23 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that … read more...

Aerie Pharmaceuticals Announces Deerfield's Conversion of Convertible Notes into Aerie Common Stock and Establishment of an Undrawn $100M Credit Facility with Deerfield

via: Business Wire at 2018-07-23 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that … read more...

Aerie Pharmaceuticals Announces Deerfield's Conversion of Convertible Notes into Aerie Common Stock and Establishment of an Undrawn $100M Credit Facility with Deerfield

via: Business Wire at 2018-07-23 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that … read more...

Aerie Pharmaceuticals Announces Early Notification of FDA Acceptance of NDA Submission for Roclatan(TM) (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% with PDUFA Date Set for March 14, 2019

via: Business Wire at 2018-07-23 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today reported that i… read more...

Aerie Pharmaceuticals Announces Early Notification of FDA Acceptance of NDA Submission for Roclatan(TM) (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% with PDUFA Date Set for March 14, 2019

via: Business Wire at 2018-07-23 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today reported that i… read more...

Aerie Pharmaceuticals Announces Early Notification of FDA Acceptance of NDA Submission for Roclatan(TM) (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% with PDUFA Date Set for March 14, 2019

via: Business Wire at 2018-07-23 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today reported that i… read more...

Aerie Pharmaceuticals Announces Early Notification of FDA Acceptance of NDA Submission for Roclatan(TM) (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% with PDUFA Date Set for March 14, 2019

via: Business Wire at 2018-07-23 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today reported that i… read more...

Aerie Pharmaceuticals Announces Appointment of Randall Brown as Director, Payer Marketing

via: Business Wire at 2018-07-16 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Ran… read more...

Aerie Pharmaceuticals Announces Appointment of Randall Brown as Director, Payer Marketing

via: Business Wire at 2018-07-16 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Ran… read more...

Aerie Pharmaceuticals Announces Appointment of Randall Brown as Director, Payer Marketing

via: Business Wire at 2018-07-16 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Ran… read more...

Liquidia To File IPO - What Investors Need To Know

via: SeekingAlpha at 2018-07-02 13:12:21:000

Liquidia Technologies ( LQDA ), has filed the necessary paperwork with the SEC to make an initial public offering. The biopharma company is seeking to raise at least $57 million and will trade on the NASDAQ Capital Market. Jefferies and Cowen will run the book on the IPO. Liquidia speciali… read more...

Liquidia To File IPO - What Investors Need To Know

via: SeekingAlpha at 2018-07-02 13:12:21:000

Liquidia Technologies ( LQDA ), has filed the necessary paperwork with the SEC to make an initial public offering. The biopharma company is seeking to raise at least $57 million and will trade on the NASDAQ Capital Market. Jefferies and Cowen will run the book on the IPO. Liquidia speciali… read more...

Liquidia To File IPO - What Investors Need To Know

via: SeekingAlpha at 2018-07-02 13:12:21:000

Liquidia Technologies ( LQDA ), has filed the necessary paperwork with the SEC to make an initial public offering. The biopharma company is seeking to raise at least $57 million and will trade on the NASDAQ Capital Market. Jefferies and Cowen will run the book on the IPO. Liquidia speciali… read more...

Aerie Pharmaceuticals - Positive Rhopressa Launch May Mark The Stock Price Peak

via: SeekingAlpha at 2018-06-26 09:03:15:000

Aerie Pharmaceuticals ( AERI ) has seen its stock soar to near all time highs over the past 20 days or so, largely on the back of a bullish earnings call and company presentation . The Good News 1. Rhopressa Launch In particular, the launch of AERIs first approved drug, … read more...

Aerie Pharmaceuticals - Positive Rhopressa Launch May Mark The Stock Price Peak

via: SeekingAlpha at 2018-06-26 09:03:15:000

Aerie Pharmaceuticals ( AERI ) has seen its stock soar to near all time highs over the past 20 days or so, largely on the back of a bullish earnings call and company presentation . The Good News 1. Rhopressa Launch In particular, the launch of AERIs first approved drug, … read more...

Aerie Pharmaceuticals - Positive Rhopressa Launch May Mark The Stock Price Peak

via: SeekingAlpha at 2018-06-26 09:03:15:000

Aerie Pharmaceuticals ( AERI ) has seen its stock soar to near all time highs over the past 20 days or so, largely on the back of a bullish earnings call and company presentation . The Good News 1. Rhopressa Launch In particular, the launch of AERIs first approved drug, … read more...

Aerie Pharmaceuticals Announces Appointment of William Coppola as Intellectual Property Counsel

via: Business Wire at 2018-06-18 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Wil… read more...

Aerie Pharmaceuticals Announces Appointment of William Coppola as Intellectual Property Counsel

via: Business Wire at 2018-06-18 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Wil… read more...

Aerie Pharmaceuticals Announces Appointment of William Coppola as Intellectual Property Counsel

via: Business Wire at 2018-06-18 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Wil… read more...

Aerie Pharmaceuticals to Present at the JMP Securities 2018 Life Science Conference

via: Business Wire at 2018-06-14 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that Richard Rubino, C… read more...

Aerie Pharmaceuticals to Present at the JMP Securities 2018 Life Science Conference

via: Business Wire at 2018-06-14 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that Richard Rubino, C… read more...

Aerie Pharmaceuticals to Present at the JMP Securities 2018 Life Science Conference

via: Business Wire at 2018-06-14 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that Richard Rubino, C… read more...

Aerie Pharmaceuticals to Present at the NASDAQ 38th Investor Conference

via: Business Wire at 2018-06-06 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that Richard Rubino, … read more...

Aerie Pharmaceuticals to Present at the NASDAQ 38th Investor Conference

via: Business Wire at 2018-06-06 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that Richard Rubino, … read more...

Aerie Pharmaceuticals to Present at the NASDAQ 38th Investor Conference

via: Business Wire at 2018-06-06 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that Richard Rubino, … read more...

Jounce: Sifting Through The Wreckage

via: SeekingAlpha at 2018-06-04 17:23:37:000

Intro To JTX-2011 The overall theory of the mechanism of action of Jounce's ( JNCE ) JTX-2011 should be easy for investors to understand. Or, at least, here is how I understood it: JTX-2011 is a "dual-role" monoclonal antibody that binds to the ICOS receptor on certain T-cells. In it… read more...

Jounce: Sifting Through The Wreckage

via: SeekingAlpha at 2018-06-04 17:23:37:000

Intro To JTX-2011 The overall theory of the mechanism of action of Jounce's ( JNCE ) JTX-2011 should be easy for investors to understand. Or, at least, here is how I understood it: JTX-2011 is a "dual-role" monoclonal antibody that binds to the ICOS receptor on certain T-cells. In it… read more...

Aerie Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

via: Business Wire at 2018-05-31 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr… read more...

Aerie Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

via: Business Wire at 2018-05-31 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr… read more...

Aerie Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

via: Business Wire at 2018-05-31 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr… read more...

Aerie Pharmaceuticals Announces Appointment of Lily Nguyen as Director, Project Management

via: Business Wire at 2018-05-30 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Lil… read more...

Aerie Pharmaceuticals Announces Appointment of Lily Nguyen as Director, Project Management

via: Business Wire at 2018-05-30 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Lil… read more...

Aerie Pharmaceuticals Announces Appointment of Lily Nguyen as Director, Project Management

via: Business Wire at 2018-05-30 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Lil… read more...

3 Things In Biotech, May 16: Lilly's No Headache, Aerie Eye's A Finish, Rexahn Swaps In Pancreatic Cancer

via: SeekingAlpha at 2018-05-17 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . And…we're back! I've spent the last half a week traveling without Internet,... read more...

Aerie Pharma submits U.S. application for eye drop Roclatan

via: SeekingAlpha at 2018-05-15 07:42:19:000

Aerie Pharmaceuticals (NASDAQ: AERI ) has filed a marketing application with the FDA seeking approval for Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a once-daily eyedrop to reduce intraocular pressure in patients with glaucoma or ocular hypertension. More news on… read more...

Aerie Pharma submits U.S. application for eye drop Roclatan

via: SeekingAlpha at 2018-05-15 07:42:19:000

Aerie Pharmaceuticals (NASDAQ: AERI ) has filed a marketing application with the FDA seeking approval for Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a once-daily eyedrop to reduce intraocular pressure in patients with glaucoma or ocular hypertension. More news on… read more...

Aerie Pharma submits U.S. application for eye drop Roclatan

via: SeekingAlpha at 2018-05-15 07:42:19:000

Aerie Pharmaceuticals (NASDAQ: AERI ) has filed a marketing application with the FDA seeking approval for Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a once-daily eyedrop to reduce intraocular pressure in patients with glaucoma or ocular hypertension. More news on… read more...

Aerie Pharma submits U.S. application for eye drop Roclatan

via: SeekingAlpha at 2018-05-15 07:42:19:000

Aerie Pharmaceuticals (NASDAQ: AERI ) has filed a marketing application with the FDA seeking approval for Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a once-daily eyedrop to reduce intraocular pressure in patients with glaucoma or ocular hypertension. More news on… read more...

Aerie Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%

via: Business Wire at 2018-05-15 06:30:00:000

- Submitted as a 505(b)(2) with an Expected Ten-Month FDA Review - Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glau… read more...

Aerie Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%

via: Business Wire at 2018-05-15 06:30:00:000

- Submitted as a 505(b)(2) with an Expected Ten-Month FDA Review - Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glau… read more...

Aerie Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%

via: Business Wire at 2018-05-15 06:30:00:000

- Submitted as a 505(b)(2) with an Expected Ten-Month FDA Review - Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glau… read more...

Aerie Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%

via: Business Wire at 2018-05-15 06:30:00:000

- Submitted as a 505(b)(2) with an Expected Ten-Month FDA Review - Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glau… read more...

Aerie Pharmaceuticals' (AERI) CEO Vincente Anido on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-09 02:43:06:000

Aerie Pharmaceuticals, Inc. (AERI) Q1 2018 Earnings Conference Call May 08, 2018, 17:00 ET Executives Richard Rubino - CFO & Secretary Vincente Anido - Chairman & CEO Thomas Mitro - President & COO Analysts Adnan Butt - Guggenheim Securities Andrew Santos - S… read more...

Aerie Pharmaceuticals' (AERI) CEO Vincente Anido on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-09 02:43:06:000

Aerie Pharmaceuticals, Inc. (AERI) Q1 2018 Earnings Conference Call May 08, 2018, 17:00 ET Executives Richard Rubino - CFO & Secretary Vincente Anido - Chairman & CEO Thomas Mitro - President & COO Analysts Adnan Butt - Guggenheim Securities Andrew Santos - S… read more...

Aerie Pharmaceuticals beats by $0.04

via: SeekingAlpha at 2018-05-08 16:24:51:000

Aerie Pharmaceuticals (NASDAQ: AERI ): Q1 EPS of -$0.83 beats by $0.04 . More news on: Aerie Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Aerie Pharmaceuticals beats by $0.04

via: SeekingAlpha at 2018-05-08 16:24:51:000

Aerie Pharmaceuticals (NASDAQ: AERI ): Q1 EPS of -$0.83 beats by $0.04 . More news on: Aerie Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Aerie Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update

via: Business Wire at 2018-05-08 16:01:00:000

Conference Call and Webcast Today, May 8 th , at 5:00 p.m. ET Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glau… read more...

Aerie Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update

via: Business Wire at 2018-05-08 16:01:00:000

Conference Call and Webcast Today, May 8 th , at 5:00 p.m. ET Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glau… read more...

Your Daily Pharma Scoop: KPTI Data, Allergan Write-Off, Celgene Down On Delay

via: SeekingAlpha at 2018-05-02 08:00:00:000

Karyopharm (KPTI) slumped 17% in the pre-market yesterday, ahead of data from a mid stage study of selinexor in treatment-resistant multiple myeloma. A couple of years ago, this same drug was pitted against Darzalex in the same indication and showed similar efficacy. An FDA filing was planned … read more...

Your Daily Pharma Scoop: KPTI Data, Allergan Write-Off, Celgene Down On Delay

via: SeekingAlpha at 2018-05-02 08:00:00:000

Karyopharm (KPTI) slumped 17% in the pre-market yesterday, ahead of data from a mid stage study of selinexor in treatment-resistant multiple myeloma. A couple of years ago, this same drug was pitted against Darzalex in the same indication and showed similar efficacy. An FDA filing was planned … read more...

Aerie Pharmaceuticals Announces Appointment of Concetta Perro as Commercial Counsel

via: Business Wire at 2018-05-01 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Con… read more...

Aerie Pharmaceuticals Announces Appointment of Concetta Perro as Commercial Counsel

via: Business Wire at 2018-05-01 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Con… read more...

Aerie Pharma launches Rhopressa in U.S.

via: SeekingAlpha at 2018-04-30 07:35:27:000

Aerie Pharmaceuticals (NASDAQ: AERI ) announces the U.S. commercial launch of Rhopressa (netarsudil ophthalmic solution) 0.02% for lowering intraocular pressure in patients with glaucoma and ocular hypertension. More news on: Aerie Pharmaceuticals, Inc., Healthcare stocks news, Read … read more...

Aerie Pharmaceuticals Announces U.S. Launch of Rhopressa® (netarsudil ophthalmic solution) 0.02%

via: Business Wire at 2018-04-30 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that it has launched R… read more...

Aerie Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Tuesday, May 8, 2018

via: Business Wire at 2018-04-26 07:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its first quarter 2018 financial results will be released after the market closes on Tuesday, May 8, 2018. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Easte… read more...

Aerie Pharmaceuticals Announces Appointment of Scott Cassady as Regional Sales Director for the Central Region

via: Business Wire at 2018-02-12 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Sco… read more...

Aerie Pharmaceuticals Announces Appointment of Scott Cassady as Regional Sales Director for the Central Region

via: Business Wire at 2018-02-12 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Sco… read more...

Aerie Pharmaceuticals Announces Appointment of Brad Fuller as Director of National Accounts in its Market Access Department

via: Business Wire at 2018-02-08 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Br… read more...

Aerie Pharmaceuticals Announces Appointment of Brad Fuller as Director of National Accounts in its Market Access Department

via: Business Wire at 2018-02-08 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Br… read more...

Aerie Pharmaceuticals Announces Appointment of Brad Fuller as Director of National Accounts in its Market Access Department

via: Business Wire at 2018-02-08 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Br… read more...

Aerie Pharmaceuticals Announces Appointment of Brad Fuller as Director of National Accounts in its Market Access Department

via: Business Wire at 2018-02-08 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Br… read more...

Aradigm: Points Of Discussion

via: SeekingAlpha at 2018-02-02 13:29:55:000

As some items are still developing (which may or may not bear fruit), this isn't going to be a full-fledged article. But, here are a six quick thoughts for Aradigm ( ARDM ) investors to consider. First, the CRL: The recommendations in the CRL include an independent third party verificati… read more...

Aradigm: Points Of Discussion

via: SeekingAlpha at 2018-02-02 13:29:55:000

As some items are still developing (which may or may not bear fruit), this isn't going to be a full-fledged article. But, here are a six quick thoughts for Aradigm ( ARDM ) investors to consider. First, the CRL: The recommendations in the CRL include an independent third party verificati… read more...

Aradigm: Points Of Discussion

via: SeekingAlpha at 2018-02-02 13:29:55:000

As some items are still developing (which may or may not bear fruit), this isn't going to be a full-fledged article. But, here are a six quick thoughts for Aradigm ( ARDM ) investors to consider. First, the CRL: The recommendations in the CRL include an independent third party verificati… read more...

Aradigm: Points Of Discussion

via: SeekingAlpha at 2018-02-02 13:29:55:000

As some items are still developing (which may or may not bear fruit), this isn't going to be a full-fledged article. But, here are a six quick thoughts for Aradigm ( ARDM ) investors to consider. First, the CRL: The recommendations in the CRL include an independent third party verificati… read more...

Aerie Pharmaceuticals Announces Appointment of Tad Heitmann as Head of Communications

via: Business Wire at 2018-02-01 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Ta… read more...

Aerie Pharmaceuticals Announces Appointment of Tad Heitmann as Head of Communications

via: Business Wire at 2018-02-01 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Ta… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-26 08:39:08:000

Zynerba Pharmaceuticals (NASDAQ: ZYNE ), BioDelivery Sciences (NASDAQ: BDSI ), Aldeyra Therapeutics (NASDAQ: ALDX ) and Aerie Pharmaceuticals (NASDAQ: AERI ) all initiated with Buy ratings at Seaport Global Securities. More news on: Zynerba Pharmaceuticals, BioDelivery Sciences Internation… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-26 08:39:08:000

Zynerba Pharmaceuticals (NASDAQ: ZYNE ), BioDelivery Sciences (NASDAQ: BDSI ), Aldeyra Therapeutics (NASDAQ: ALDX ) and Aerie Pharmaceuticals (NASDAQ: AERI ) all initiated with Buy ratings at Seaport Global Securities. More news on: Zynerba Pharmaceuticals, BioDelivery Sciences Internation… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-26 08:39:08:000

Zynerba Pharmaceuticals (NASDAQ: ZYNE ), BioDelivery Sciences (NASDAQ: BDSI ), Aldeyra Therapeutics (NASDAQ: ALDX ) and Aerie Pharmaceuticals (NASDAQ: AERI ) all initiated with Buy ratings at Seaport Global Securities. More news on: Zynerba Pharmaceuticals, BioDelivery Sciences Internation… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-26 08:39:08:000

Zynerba Pharmaceuticals (NASDAQ: ZYNE ), BioDelivery Sciences (NASDAQ: BDSI ), Aldeyra Therapeutics (NASDAQ: ALDX ) and Aerie Pharmaceuticals (NASDAQ: AERI ) all initiated with Buy ratings at Seaport Global Securities. More news on: Zynerba Pharmaceuticals, BioDelivery Sciences Internation… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-26 08:39:08:000

Zynerba Pharmaceuticals (NASDAQ: ZYNE ), BioDelivery Sciences (NASDAQ: BDSI ), Aldeyra Therapeutics (NASDAQ: ALDX ) and Aerie Pharmaceuticals (NASDAQ: AERI ) all initiated with Buy ratings at Seaport Global Securities. More news on: Zynerba Pharmaceuticals, BioDelivery Sciences Internation… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-26 08:39:08:000

Zynerba Pharmaceuticals (NASDAQ: ZYNE ), BioDelivery Sciences (NASDAQ: BDSI ), Aldeyra Therapeutics (NASDAQ: ALDX ) and Aerie Pharmaceuticals (NASDAQ: AERI ) all initiated with Buy ratings at Seaport Global Securities. More news on: Zynerba Pharmaceuticals, BioDelivery Sciences Internation… read more...

Your Daily Pharma Scoop: Portola Still Attractive, Johnson & Johnson Reports Q4 Results, Cerus Reports Positive Results

via: SeekingAlpha at 2018-01-25 08:00:00:000

Analysis of top Seeking Alpha coverage: Portola Today we will focus on Portola Pharmaceuticals ( PTLA ), which had an excellent 2017. PTLA has made a decent start to 2018 as well, gaining more than 4%. Earlier this week, PTLA announced an abstract providing interim results from its ong… read more...

Your Daily Pharma Scoop: Portola Still Attractive, Johnson & Johnson Reports Q4 Results, Cerus Reports Positive Results

via: SeekingAlpha at 2018-01-25 08:00:00:000

Analysis of top Seeking Alpha coverage: Portola Today we will focus on Portola Pharmaceuticals ( PTLA ), which had an excellent 2017. PTLA has made a decent start to 2018 as well, gaining more than 4%. Earlier this week, PTLA announced an abstract providing interim results from its ong… read more...

Biotech Forum Daily Digest For January 24th

via: SeekingAlpha at 2018-01-24 10:13:06:000

No matter how long you train someone to be brave, you never know if they are or not until something real happens . Veronica Roth, Insurgent The biotech sector got off to a stunning start to the trading week on Monday. Celgene ( CELG ) acquired Juno Therapeutics ( JUN… read more...

Aerie Pharma commences $75M stock offering

via: SeekingAlpha at 2018-01-24 07:03:05:000

Aerie Pharmaceuticals (NASDAQ: AERI ) says it has " priced " its $75M public offering of common stock but provides no set price. Cantor Fitzgerald is the sole book runner and may sell shares at-the-market or discounted through negotiated transactions. Closing date is January 26. More news … read more...

Aerie Pharmaceuticals Announces Public Offering of Common Stock

via: Business Wire at 2018-01-23 16:03:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma or ocular hypertension and other diseases of the eye, today announced that it ha… read more...

Aerie Pharmaceuticals Announces Appointments of Nils Hauptmann as Director of Regulatory Affairs and Pharmacovigilance and Tim Swan as Director of Sales and Transparency Operations

via: Business Wire at 2018-01-16 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointments of N… read more...

Aerie Pharmaceuticals Announces Appointment of Julia Williams as Director of Medical Affairs

via: Business Wire at 2018-01-02 06:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Ju… read more...

3 Bold Biotech Predictions For 2018!

via: SeekingAlpha at 2017-12-26 12:53:37:000

Nothing is born into this world without labor. Rob Liano It is hard to believe but 2017 is rapidly coming to a close. It has been a solid year for biotech investors. After under performing the overall market significantly in 2015 and 2016, the biotech sector largely perf… read more...

Your Daily Pharma Scoop: Synergy's New CEO, AbbVie Data, TiGenix Changes

via: SeekingAlpha at 2017-12-21 02:41:58:000

Content Analysis of coverage: SGYP Stocks in the news: ABBV, TIG, EGLT Analyst Ratings Insider Sales Insider Purchases Secondary Offerings Earnings Report Earnings Calendar Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today … read more...

Biotech Forum Daily Digest: Aerie Pharmaceuticals Garners Early FDA Approval

via: SeekingAlpha at 2017-12-20 11:30:31:000

The role of the artist is to ask questions, not answer them . Anton Chekhov The year is rapidly coming to a close. The major indices are at or near all-time highs with the S&P 500 up over 20% for 2017 including dividends. After a dismal 2015 & 2016, the biotech se… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX